Quidel Corp

Quidel Corp Stock Forecast & Price Prediction

Live Quidel Corp Stock (QDEL) Price
$41.76

3

Ratings

  • Buy 1
  • Hold 1
  • Sell 1
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$41.76

P/E Ratio

P/E Ratio not available for QDEL

Volume Traded Today

$2.6M

Dividend

Dividends not available for QDEL

52 Week High/low

98.67/41.75

Quidel Corp Market Cap

$2.79B

🛑 Alert: These ten stocks could have higher potential than $QDEL 🛑

Before you buy QDEL you’ll want to see this list of ten stocks that have huge potential. Want to see if QDEL made the cut? Enter your email below

QDEL Summary

Based on ratings from 3 stock analysts, the Quidel Corp stock price is expected to increase by 51.65% in 12 months. This is calculated by using the average 12-month stock price forecast for Quidel Corp. The lowest target is $37.00 and the highest is $81.00. Please note analyst price targets are not guaranteed and could be missed completely.

QDEL Analyst Ratings

About 3 Wall Street analysts have assignedQDEL 1 buy ratings, 1 hold ratings, and 1 sell ratings. This means that analysts expect Quidel Corp to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on QDEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

QDEL stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

casey woodring
J.P. Morgan

Sell

$37.0

downgraded

Feb 14, 2024
conor mcnamara
RBC Capital

Buy

$81.0

maintained

Feb 14, 2024
alexander nowak
Craig-Hallum

Buy

None

rated

Dec 21, 2023
patrick b donnelly
Citi

Hold

$72.0

downgraded

Dec 11, 2023
andrew cooper
Raymond James

Buy

$130.0

reiterated

May 4, 2023
steven mah
Cowen & Co.

Buy

$140.0

maintained

Jul 26, 2021
tycho peterson
J.P. Morgan

Sell

$80.0

maintained

Jun 4, 2021
brian weinstein
William Blair

Buy

None

reiterated

May 7, 2021
jack meehan
Nephron

Hold

$90.0

downgraded

Mar 26, 2020
john hsu
Raymond James

Hold

None

downgraded

Mar 19, 2020
mark massaro
BTIG

Buy

$75.0

maintained

Nov 17, 2019
nicholas jansen
Raymond James

Buy

$60.0

maintained

Apr 3, 2018
john ransom
Raymond James

Buy

$55.0

reiterated

Mar 1, 2018
david westenberg
Piper Sandler

Buy

$52.0

upgraded

Jan 4, 2018
ryan daniels
William Blair

Buy

None

reiterated

Jul 28, 2017
william bonello
Craig-Hallum

Hold

$18.0

downgraded

Oct 23, 2015
jeffrey frelick
Canaccord Genuity

Buy

$34.0

rated

Nov 10, 2014
zarak khurshid
Wedbush

Hold

$20.0

upgraded

Jul 23, 2014
j t haresco
JMP Securities

Hold

None

initiatedcoverage

Dec 18, 2013
shaun rodriguez
Cowen & Co.

Hold

None

rated

Oct 2, 2012

QDEL Company Information

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

QDEL
Quidel Corp (QDEL)

When did it IPO

0

Staff Count

7,000

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Douglas C. Bryant

Market Cap

$2.79B

Quidel Corp(QDEL) Financial Data

In 2023, QDEL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that QDEL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $3.00B
  • Operating Margin TTM 0.10%
  • Gross profit TTM $1.94B
  • Return on assets TTM 0.02%
  • Return on equity TTM 0.00%
  • Profit margin -0.00337%
  • Book value 74.83%
  • Market capitalisation $2.79B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year -0.15
  • EPS next year N/A

Quidel Corp(QDEL) Latest News

... ...

Similar Stocks to Quidel Corp QDEL

🛑 Alert: These ten stocks could have higher potential than $QDEL 🛑

Before you buy QDEL you’ll want to see this list of ten stocks that have huge potential. Want to see if QDEL made the cut? Enter your email below

...

QDEL Frequently asked questions

The highest forecasted price for QDEL is $81.00 from conor mcnamara at RBC Capital.

The lowest forecasted price for QDEL is $37.00 from casey woodring from J.P. Morgan

The QDEL analyst ratings consensus are 1 buy ratings, 1 hold ratings, and 1 sell ratings.